Clinically Relevant Doses of Enalapril Mitigate Multiple Organ Radiation Injury

Radiation Research

Volumn 185, Issue 3, 2016, Pages 313-318

  Cohen, Eric P ^a   Fish, Brian L ^b   Moulder, John E ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE RADIATION SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; HUMAN; KIDNEY INJURY; LUNG INJURY; MALE; MORBIDITY; NONHUMAN; PARTIAL BODY RADIATION; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RAT; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL; ANIMAL; AZOTEMIA; DRUG EFFECTS; INJURIES; KIDNEY; PATHOLOGY; RADIATION INJURIES, EXPERIMENTAL; RADIATION RESPONSE; WHOLE BODY RADIATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AZOTEMIA; ENALAPRIL; HUMANS; KIDNEY; RADIATION INJURIES, EXPERIMENTAL; RATS; WHOLE-BODY IRRADIATION;

EID: 84979768768     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR4243.S1     Document Type: Article

References (27)

1. Moulder JE. The 2013 Dade W. Moeller Lecture: Medical countermeasures against radiological terrorism. Health Phys 2014; 170:164-71.
2. Cohen EP, Bedi M, Irving AA, Jacobs ER, Tomic R, Klein JP, et al. Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation. Int J Radiat Oncol Biol Phys 2012; 83:292-6.
3. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop, December 3-4, 2003. Radiat Res 2004; 162:711-28.
4. Moulder JE, Fish BL. Late toxicity of total body irradiation with bone marrow transplantation in a rat model. Int J Radiat Oncol Biol Phys 1989; 16:1501-9.
5. Zhang R, Ghosh SN, Zhu D, North PE, Fish BL, Morrow NV, et al. Structural and functional alterations in the rat lung following whole thoracic irradiation with moderate doses: injury and recovery. Int J Radiat Biol 2008; 84:487-97.
6. Medhora M, Gao F, Jacobs ER, Moulder JE. Radiation damage to the lung: Mitigation by angiotensin-converting enzyme (ACE) inhibitors. Respirology 2012; 17:66-71.
7. Moulder JE, Cohen EP, Fish BL. Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors. Int J Radiat Biol 2014; 90:762-8.
8. Kma L, Gao F, Fish BL, Moulder JE, Jacobs ER, Medhora M. Angiotensin converting enzyme inhibitors mitigate collagen synthesis induced by a single dose of radiation to the whole thorax. J Radiat Res 2012; 32:10-7.
9. Moulder JE, Cohen EP, Fish BL. Captopril and losartan for mitigation of renal injury caused by single-dose total body irradiation. Radiat Res 2011; 175:29-36.
10. Finney DJ. Statistical methods in biological assay. New York: MacMillan Publishing Co; 1978.
11. Moulder JE, Fish BL. Angiotensin converting enzyme inhibitor captopril does not prevent acute gastrointestinal radiation damage in the rat. Radiat Oncol Invest 1997; 5:50-3.
12. Moulder JE, Fish BL, Cohen EP, Klein JP. Re: Davis et al., Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol 2011; 39:521-2.
13. Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987; 31:752-9.
14. Juncos LI, Carrasco Dueñas S, Cornejo JC, Broglia CA, Cejas H. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron 1993; 64:249-55.
15. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 1993; 27:93-9.
16. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40:195-202.
17. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New Eng J Med 1991; 325:293-302.
18. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, et al. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70-8.
19. Cohen EP, Moulder JE, Fish BL, Hill P. Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med 1994; 124:371-80.
20. Gao F, Fish BL, Moulder JE, Jacobs ER, Medhora M. Enalapril mitigates radiation-induced pneumonitis and pulmonary fibrosis if started 35 days after whole-thorax irradiation. Radiat Res 2013; 180:546-52.
21. Moulder JE, Fish BL, Cohen EP. Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol 1998; 46:307-15.
22. Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Follath F. Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events. J Pharmacol Exper Ther 1999; 289:565-71.
23. Johnston CI, Jackson BJ, Larmour I, Cubella R, Casley D. Plasma enalapril levels and hormonal effects after short-and long-term administration in essential hypertension. Br J Clin Pharmacol 1984; 18 (Suppl. 2):233S-41S.
24. Elung-Jensen T, Heisterberg J, Sonne J, Strandgaard S, Kamper AL. Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. Eur J Clin Pharm 2005; 61:87-96.
25. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acidinduced endothelial dysfunction. J Hypertension 2010; 28:1234-42.
26. Otterson MF, Leming SC, Callison J, Moulder JE, Cohen EP. Safety of enalapril after abdominal irradiation. J Invest Med 2012; 60:726.
27. MacVittie TJ. The MCART consortium animal models series. Health Phys 2012; 103:340-2.